

1 Comparison and analysis of various complementary diagnosis methods 2 for the current situation and problems of COVID-19 diagnosis

3
4 Hee Jin Huh¹, Seok Lae Chae¹, Dong-Min Kim^{2,*}

5 ¹Department of Laboratory Medicine Dongguk University Ilsan hospital.

6 ²Department of Internal Medicine, College of Medicine, Chosun University, 588 Seosuk-dong, Dong-gu, Gwangju
7 61453, Republic of Korea.

8 *Correspondence and requests for materials should be addressed to Dong-Min Kim (Tel: 82-62-220-3108; Fax: 82-
9 62- 234-965; E-mail address: drongkim@chosun.ac.kr)

10 Article received/accepted date, online published date

11 © Society and Springer 2010

12

13 **Abstract**

14 We evaluated and compared the diagnostic performance of fluorescence immunoassay (FIA) and two types of
15 serological diagnostic tests: enzyme-linked immunosorbent assay (ELISA) and immunochromatographic assay
16 (ICA) for detection of SARS-CoV-2 antigen and antibody to diagnose COVID-19 infections. This study is aimed to
17 analyze and compare the current status and problems of COVID-19 diagnosis and various alternative diagnostic
18 methods that are viable. The enrolled subjects in our study population were tested with real-time polymerase chain
19 reaction (RT-PCR). ELISA and immunochromatographic diagnostic kit were used to diagnose 362 positive and
20 3010 negative SARS-CoV-2 specimens, and antigen fluorescence immunoassay kit was used on 62 positive and 70
21 negative SARS-CoV-2 RT-PCR confirmed samples for diagnosis. As a result, categorizing by the patient symptom
22 onset days, PCL COVID19 Total Ab EIA (ELISA) showed the sensitivity of 93.4% from 15 to 21 days, 94.2% from
23 over 22 days, and the specificity of 99.97%. PCL COVID19 IgG/IgM Rapid Gold (ICA) had a sensitivity of 86.9%,
24 97.4%, and the specificity of 98.14% respectively. PCL COVID19 Ag Rapid FIA sensitivity was 93.8% from 0 to 7
25 days, 71.4% from 8 to 12 days and specificity was 98.57%. In conclusion, COVID-19 Ab ELISA and ICA, and
26 COVID-19 Ag FIA are all complementary and applicable diagnostic methods to resolve the current problems of
27 COVID-19 diagnosis.

28

29 **KEYWORDS**

30 **COVID-19, ELISA, Fluorescent Immunoassay, immunochromatography, real-time polymerase chain**
31 **reaction**

32

33 **Introduction:**

1 With the first identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
2 in December 2019 from Wuhan, Hubei Province, China, coronavirus disease 2019 (COVID-19)
3 was soon after declared as a pandemic in March 2020 by World Health Organization (WHO)¹.
4 The virus has not ceased to spread until now, resulting in tremendous public health challenges
5 across the world with over 61 million confirmed cases reported worldwide as of 30 November
6 2020^{2, 3}.

7 COVID-19 diagnostic test samples are obtained from either a patient's blood or naso-
8 oropharyngeal specimen. Molecular diagnostic tests, such as next generation sequencing or real-
9 time polymerase chain reaction (RT-PCR), have been recommended to detect SARS-CoV-2
10 from the upper and lower respiratory tract swab samples for COVID-19 diagnosis³⁻⁷. However,
11 this method requires at least for 6 or more hours, to accurately process and determine the
12 COVID-19 infection of a patient⁸. In many cases where steep COVID-19 surges occur,
13 performing the molecular tests in a timely manner to close the gap between the high number of
14 patients and the limited number of laboratories has been a critical hinderance from devising of
15 efficient containment strategies for COVID-19 in many countries⁹.

16 In order to solve this problem, serological tests such as enzyme-linked immunosorbent assay
17 (ELISA) and immunochromatography have been developed to detect antibodies and antigens of
18 a virus. These methods now have become commercialized and can be easily accessed. This
19 allows to play a crucial role in overcoming the limitation of molecular diagnostic test as
20 alternative assays with the advantages such as ability to test large numbers of samples more
21 rapidly with less cost and perform an epidemiologic tracing in a short period of time^{10, 11}.

22 Proper isolation and timely detection through a rapid diagnosis of COVID-19 is critical to
23 prevent the spreading of infection among the patients with recurrence of COVID-19, and to
24 decrease the associated prevalence and mortality rates due to unforeseen waves of the pandemic⁸,
25 ¹². Therefore, we evaluated and compared the diagnostic performance of two types of serological
26 diagnostic test ELISA and ICA for antibody detection and FIA for antigen detection of SARS-
27 CoV-2.

28

29

30 **Methods:**

1 **Study Design for serological test**

2 A total of 50 patients diagnosed as COVID-19 positive were enrolled in this study. All enrolled
3 patients were confirmed to be infected with SARS-CoV-2 by the RT-PCR assays using
4 nasopharyngeal swabs. In the case of negative samples, 1072 residual samples were collected
5 from 1072 healthy people assessed by physical examination during early November of 2019,
6 before the pandemic of COVID-19, and the others collected from healthy donors without any
7 COVID-19 symptoms. A total of 3,372 human blood samples (serum), 362 COVID-19 positive
8 samples and 3,010 negative samples were used for this study. Regarding anticoagulant, 3372
9 serum samples were separated with gel without any anticoagulants. Positive and negative blood
10 samples for COVID-19 were used for the performance evaluation of the PCL COVID-19 Total
11 Ab EIA and the PCL COVID19 IgG/IgM Rapid Gold at DUMC under respective IRB approval
12 (DUIH 2020-03-025-003 and 110757-202003-HR-02-02). The performance evaluation was
13 conducted retrospectively by comparing the information including test results of the RT-PCR
14 COVID-19.

15 **Study Design for Antigen test**

16 In case of antigen test, we used nasopharyngeal swab samples in viral transport medium (VTM)
17 and the extraction buffer (the PCL COVID19 Ag Rapid FIA kit). A total of 132 nasopharyngeal
18 swab samples stored in VTM, including 62 positives and 70 negatives for the COVID-19, were
19 used for the retrospective performance evaluation of the PCL COVID19 Ag Rapid FIA at 2
20 institutions under respective IRB approval (S-IRB-2020-004-04-08 and IRB-2020-01-027).
21 Nasopharyngeal swab samples were collected from individuals diagnosed as positive or negative
22 by RT-PCR testing (PowerChek™2019-nCoV Real-time PCR Kit, Kogenebiotech, Seoul,
23 Korea).

24

25 **RT-PCR confirmation assay**

26 Nasopharyngeal swabs were obtained from each patient for RT-PCR, which was performed
27 using the CFX96™ Real-time PCR detection system (Bio-Rad Laboratories, Hercules, CA) with

1 the Allplex™ 2019-nCoV Assay kit (Seegene Inc., Seoul, Korea) according to the
2 manufacturer's instructions. The assay is designed to detect RdRP and N genes specific for
3 SARS-CoV-2, and E gene for all of *Sarbecovirus* including SARS-CoV-2.

4

5 **Serologic test for detection of antibodies against SARS-CoV-2**

6 Lateral flow immunochromatographic assay (LFA)

7 To evaluate SARS-CoV-2 specific IgM and IgG antibodies, the LFA based rapid test (PCL
8 COVID19 IgG/IgM Rapid Gold) was performed following the manufacturer's instructions. Each
9 sample was tested by one test and readout (positive/negative) interpreted by two operators in
10 parallel.

11

12 Enzyme-linked immunosorbent assay (ELISA)

13 To evaluate total antibody response, the ELISA (PCL COVID19 Total Ab EIA test, PCL Inc.,
14 Seoul, Korea) was performed following the manufacturer's instructions. All tests were performed
15 in duplicate, according to the manufacturer's instructions and Absorbance/cut-off values ≥ 1.0
16 were considered positive.

17

18 Fluorescence Immunochromatographic Assay (FIA)

19 To detect the SARS-CoV-2 virus infection, the rapid FIA kit (PCL COVID19 Ag Rapid FIA),
20 which is used with the PCLOK EZ analyzer for the qualitative detection from SARS-CoV-2 in
21 nasopharyngeal specimens from individuals who are suspected of COVID-19 by their healthcare
22 provider, was performed following the manufacturer's instrument.

23

24 **Statistical analysis**

1 The sensitivity, specificity, positive predictive value (PPV), and negative predictive value
2 (NPV) were calculated, along with the 95% confidence interval (CI). A diagnostic value test of
3 the ELISA and rapid antibody method was performed with MedCalc software, version 19.5.1
4 (Mariakerke, Belgium).

5

6 **Results**

7 **Population of study sample**

8 The overall contents of the study population are described (Table 1). For the Ab test, 362 blood
9 samples were collected from 50 patients identified as COVID-19 positive via RT-PCR test and
10 3010 negative blood samples were collected from 3010 individuals. For the Ag test, 62 positive
11 and 70 negative samples identified as COVID-19 were collected through RT-PCR testing. Each
12 population was categorized by patient specimen collection dates, the presence of COVID-19
13 symptoms, pre-existing disease, and age.

14

15 **Result of SARS-CoV2 Ab test**

16 In order to compare the positive rate of PCL COVID19 Total Ab EIA and PCL COVID19
17 IgG/IgM Rapid Gold to RT-PCR, the obtained results were first categorized into 4 groups by the
18 length of days after symptom onset: 0-7 days, 8-14 days, 15-21 days, and 22+ days. The positive
19 rate of PCL COVID19 Total Ab EIA diagnostic results for 362 samples, confirmed positive with
20 RT-PCR, was 40% (95% CI 24.86-56.67%), 65.7% (95% CI 53.40-76.65%), 93.4% (95% CI
21 84.05-98.18%) and 94.2% (95% CI 89.93-97.09%) respectively. For IgG & IgM combined
22 positive rates of PCL COVID19 IgG/IgM Rapid Gold diagnostics for 362 identical samples was
23 42.5% (95% CI 27.04-59.11%), 64.3% (95% CI 51.93-75.39%), 86.9% (95% CI 75.78-94.16%),
24 and 97.4% (95% CI 94.00-99.14%) respectively. We also measured the positive rate marked
25 with IgG and IgM individually; IgG showed a result of 32.5% (95% CI 18.57-49.13%), 50.0%
26 (95% CI 37.80-62.20%), 83.6% (95% CI 71.91-91.85%) and 97.4% (95% CI 94.00-99.14%),
27 and IgM showed 37.5% (95% CI 22.73-54.20%), 51.4% (95% CI 39.17-63.56%), 77.0% (95%
28 CI 64.5-86.85%), and 65.4% (95% CI 58.24-72.16%) accordingly. This data demonstrated that

1 IgG and IgM showed a similar positive rate until the 14 days period, but we noticed that the
2 positive rate of IgG began to gradually increase from 14 days and onwards (Figure1).

3 For PCL COVID19 Total Ab EIA, specificity was measured with a total of 3010 individual
4 serum samples. Only 1 out of 3010 negative samples was a false negative, resulting in specificity
5 of 99.97% (95% CI 99.82-100%) (Table 2). For PCL COVID19 IgG/IgM Rapid Gold, out of
6 3010 negative samples, 2954 samples were diagnosed as negative and the rest of 56 samples
7 came out as false positives, showed a specificity of 98.14% (95% CI 97.59-98.59%) (Table2).

8 Within the 50 COVID-19 positive patient groups, seroconversion has occurred to 16 of them
9 and we decided to analyze the effect of seroconverted samples on positive rate results of PCL
10 COVID19 Total Ab EIA diagnostic kit. This data was also categorized by the length of days
11 after symptom onset of the patient: 0-7 days, 8-14 days, 15-21 days, and 22+ days, and the result
12 showed as 17.4% (95% CI 4.95-38.78%), 51.2% (95% CI 35.13-67.12%), 90.5% (95% CI 69.62-
13 98.83%), and 92.1% (95% CI 84.99-96.52%) respectively (Figure 2). For antibody detection
14 diagnostics, we observed that the positive rate dramatically increases after 14 days from the
15 infection of the virus.

16 In addition, by comparing the results from patients with the presence or absence of disease
17 (Figure 4B), it was confirmed that the antibody concentration was high in patients with
18 underlying disease.

19 Taken together, it seems that SARS-CoV-2 antibody should be tested after 14 days of infection,
20 and SARS-CoV-2 antigen should be tested within 14 days of infection.

21

22 **Result of SARS-CoV2 Ag test**

23 We used PCL COVID19 Ag Rapid FIA to distinguish the patients who have been infected for
24 less than 14 days. With having all 62 samples already confirmed positive with RT-PCR test (0-
25 12 days after symptom onset), the test result demonstrated that sensitivity was 93.8% (95% CI
26 82.80-98.69%) for 0-7 days period and 71.4% (95% CI 41.90-91.61%) for 8-12 days period
27 (Figure 3). We can conclude that the positive rate for antigen-based tests decreases as days go by
28 from the initial symptom onset period of a patient. Specificity was measured with a total of 70
29 RT-PCR confirmed negative samples, and only 1 out of 70 samples was false negative, resulting
30 in specificity of 98.57% (95% CI 92.30-99.96%) (Table 2).

31

1

2 **Discussion**

3 In Wuhan, Hubei Province, China, coronavirus disease 2019 (COVID-19) was declared a
4 pandemic in March 2020 by the World Health Organization (WHO) with the first detection of
5 extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019¹. The
6 WHO announced that Chinese authorities had identified a novel type of coronavirus in January 7
7 2020¹³. RT-PCR, a nucleic acid amplification test (NAAT), was used as a COVID-19 diagnostic
8 test in many countries around the world, since the new coronavirus was identified⁴⁻⁷. However,
9 the RT-PCR test takes a lot of time to accurately diagnose the infection. To combat the current
10 COVID-19 pandemic, an efficient strategy for diagnosis of asymptomatic infections is required
11 because it is difficult to discern solely with a symptom-based RT-PCR screening. Asymptomatic
12 cases are reported to be 20 to 40% of the total incidence, or even higher, considering the
13 percentage of undetected COVID-19 infections^{14, 15}. Although there have been no cases
14 previously with the Middle East Respiratory Syndrome coronavirus (MERS-CoV), current
15 investigations have shown that asymptomatic and mild COVID-19 patients can produce
16 detectable levels of antibodies against SARS-CoV-19. To manage these problems, the need for
17 an alternative analysis that enables a large number of diagnoses in a short time at low cost has
18 emerged. In fact, RT-PCR test does not satisfy the field where antibody results are required
19 because antibody test results cannot be obtained through RT-PCR test. In this study,
20 complementary diagnostic products to RT-PCR will be reviewed for COVID-19 detection. These
21 products are COVID-19 total Ab ELISA: PCL COVID19 Total Ab EIA, COVID-19 spike
22 protein, nucleocapsid protein antibody immunochromatographic rapid test: PCL COVID19
23 IgG/IgM Rapid Gold, and COVID-19 nucleocapsid protein antigen fluorescent immunoassay
24 rapid test: PCL COVID19 Ag Rapid FIA. All of the above reagents are a dedicated detection
25 reagent for the SARS-Cov 2.

26 Coronavirus is a single-stranded RNA virus that uses spike protein to enter host cells.
27 Coronavirus is composed of spike protein, membrane protein, envelope protein, and
28 nucleocapsid protein^{4, 13}. In general, the diagnosis of COVID-19 infection is made using RT-
29 PCR. While RT-PCR remains an effective microbial diagnostics technique, however, when used
30 alone in the areas of confirming COVID-19, there are some limitations or weaknesses, such as

1 the inability to differentiate virus viability and the development of indeterminate or false-
2 negative results due to low target cell numbers in specimens¹⁶. To manage these problems,
3 different methods of diagnosis were required for suspected and supervised COVID-19
4 infections.

5 From the aforementioned reasons, complementary diagnosis is required in addition to the RT-
6 PCR-based diagnostic method. Among them, COVID-19 Ab Enzyme-Linked Immunosorbent
7 Assay (ELISA), COVID-19 Ab Immunochromatographic rapid test, and COVID-19 Antigen
8 Fluorescent Immunoassay rapid test can be used. ELISA has proven its validity as a diagnostic
9 method for a long time since it was published by Peter Perlmann and Eva Engvall in 1971. The
10 fact that ELISA can be implemented to a large-scale automatized equipment makes it a suitable
11 complementary diagnosis method regarding the current issue with the COVID-19 pandemic.
12 Immunochromatography was developed with the aim of detecting antigens in blood in the late
13 1960s and has been validated as a diagnostic method for various infections. The advantages
14 of immunochromatography are its simple test methods, significantly shorter time required to
15 prepare samples and reagents compared to other methods, and inexpensive equipment required
16 for making a diagnosis. Also, it can be applied in various environments both indoor and outdoor
17 settings. Immunochromatography is a suitable complementary diagnosis method for RT-PCR
18 test which has limitations such as operation time, operable environment, and number of samples
19 the test can diagnose at once. Lastly, the COVID-19 Nucleocapsid protein Antigen Fluorescent
20 Immunoassay has gone through major developmental breakthroughs over the years, and has
21 shown prominence in reagent simplification, simple analysis design, and high-sensitivity
22 detection. Fluorescent Immunoassay uses a fluorescent compound that absorbs light or energy of
23 a specific wavelength and emits light or energy at another wavelength. This fluorescent
24 compound offers an advantage of being able to check the results in a short time using a small
25 analyzer as a detection reagent.

26 PCL COVID19 Total Ab EIA (ELISA) showed the sensitivity of 93.4% from 15 to 21 days,
27 94.2% from over 22 day, and the specificity of 99.97%. PCL COVID19 IgG/IgM Rapid Gold
28 (ICA) had a sensitivity of 86.9%, 97.4%, and the specificity of 98.14% respectively. PCL
29 COVID19 Ag Rapid FIA sensitivity was 93.8% from 0 to 7 days, 71.4% from 8 to 12 day and
30 specificity was 98.57%. As a result, these diagnostic methods can be used as a complement to

1 the current diagnosis of COVID-19, before 14days of infection, SARS-CoV-2 antigen should be
2 tested and after 14days of infection, SARS-CoV-2 antibody should be tested.

3 **Acknowledgements** This study was supported by the Promising IP Project Support Program
4 (grant number: 20001089) funded by the Ministry of Trade Industry and Energy. And this study
5 was supported by the Clinical Trial Support Program (grant number: HI18C1849) funded by the
6 Ministry of Health and Warfare. Also, this study was supported by the Technological Innovation
7 R&D Program (grant number: HI20C0371010120) funded by the Korea Health Industry
8 Development Institute (KHIDI).

9

10 References:

11


- 12 1. World Health Organization. Timeline of WHO's response to COVID-19. Available
13 from: <https://www.who.int/news/item/29-06-2020-covidtimeline>. (2020)
- 14 2. World Health Organization. A Coordinated Global Research Roadmap. Available from:
15 <https://www.who.int/publications/m/item/a-coordinated-global-research-roadmap>. (2020)
- 16 3. World Health Organization. Coronavirus Disease (COVID-19) Outbreak Situation.
17 Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.
18 (2020)
- 19 4. Lu, R., et al., Genomic characterisation and epidemiology of 2019 novel coronavirus:
20 implications for virus origins and receptor binding. *Lancet*, **395**, 565-574 (2020)
- 21 5. Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in
22 Wuhan, China. *Lancet*, **395**, 497-506 (2020)
- 23 6. Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel
24 coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*, **395**, 507-513
25 (2020)
- 26 7. Guan, W.J., et al., Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl*
27 *J Med*, **382**, 1708-1720 (2020)
- 28 8. Choe, J.Y., et al., Diagnostic performance of immunochromatography assay for rapid
29 detection of IgM and IgG in coronavirus disease 2019. *J Med Virol*, (2020)

- 1 9. World Health Organization. Laboratory testing strategy recommendations for COVID-
2 19: interim guidance, 21 March 2020. Available from:
3 <https://apps.who.int/iris/handle/10665/331509>. (2020)
- 4 10. Ko, J.H., et al., Neutralizing Antibody Production in Asymptomatic and Mild COVID-19
5 Patients, in Comparison with Pneumonic COVID-19 Patients. *J Clin Med*, **9** (2020)
- 6 11. Porte, L., et al., Evaluation of a novel antigen-based rapid detection test for the diagnosis
7 of SARS-CoV-2 in respiratory samples. *Int J Infect Dis*, **99**, 328-333 (2020)
- 8 12. Nguyen, T., D. Duong Bang, and A. Wolff, 2019 Novel Coronavirus Disease (COVID-
9 19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics. *Micromachines*
10 (*Basel*), **11** (2020)
- 11 13. World Health Organization. Novel Coronavirus (2019-nCoV) situation report-1.
12 Available from: [https://www.who.int/docs/default-source/coronaviruse/situation-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf)
13 [reports/20200121-sitrep-1-2019-ncov.pdf](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf). (2020)
- 14 14. Huff, H.V. and A. Singh, Asymptomatic transmission during the COVID-19 pandemic
15 and implications for public health strategies. *Clin Infect Dis*, (2020)
- 16 15. Oran, D.P. and E.J. Topol, Prevalence of Asymptomatic SARS-CoV-2 Infection : A
17 Narrative Review. *Ann Intern Med*, **173**, 362-367 (2020)
- 18 16. Kralik, P. and M. Ricchi, A Basic Guide to Real Time PCR in Microbial Diagnostics:
19 Definitions, Parameters, and Everything. *Front Microbiol*, **8**, 108 (2017)
20

1 Table 1. Clinical characteristics of study population

		SARS-CoV-2 Ab test		SARS-CoV-2 Ag test	
		Positive	Negative	Positive	Negative
Total		362	3010	62	70
Age range (avg.)		1-88 (59.8)	-	-	-
Disease	Y	207	-	-	-
	N	155	-	-	-
Days post symptom	0-7	40	-	-	-
	8-14	70	-	-	-
	15-21	61	-	-	-
	22+	191	-	-	-


2
3



		Pos sample No.				Pos rate %			
Day	Total sample No*	ELISA	M or G	M	G	ELISA	M or G	M	G
0~7	40	16	17	15	13	40.0%	42.5%	37.5%	32.5%
8~14	70	46	45	36	35	65.7%	64.3%	51.4%	50.0%
15~21	61	57	53	47	51	93.4%	86.9%	77.0%	83.6%
22+	191	180	186	125	186	94.2%	97.4%	65.4%	97.4%

1
 2 **Figure 1. Graph and table of positive rates of total antibody, IgG and IgM and days after**
 3 **symptom onset.** Positive rates for the total antibody(measured by PCL COVID19 Total Ab
 4 EIA), IgG/IgM(measured by PCL COVID19 IgG / IgM Rapid Gold), were determined in 362
 5 serum samples from 50 patients according to the days after symptom onset.

6



1

2 **Figure 2. Levels of antibodies against SARS-CoV-2 in patient samples at different times**

3 **after symptom onset.** SARS-CoV-2 antibody levels were measured for various periods in 16

4 patients with seroconversion, and the positive rate of antibodies measured within each week was

5 plotted on the graph. The X shape is less than S/CO 1, the point is S/CO 1 or more. The red

6 dotted line is S/CO 1(equal to cutoff)


7

1 **Table 2. Results of negative test for each kit**

	PCL COVID19 Total Ab EIA	PCL COVID19 IgG/IgM Rapid gold	PCL COVID19 Ag Rapid FIA
Total sample	3010	3010	70
Positive	1	56	1
Negative	3009	2954	69
Specificity	99.97%	98.14%	98.57%

2

3




Day	Total sample No*.	Pos sample No.	Pos rate %
0~7	48	45	93.8%
8~12	14	10	71.4%

1
2
3
4
5

Figure 3. Graphs of positive rates and days after symptom onset of PCL COVID19 Ag

Rapid FIA. The positive rate is the result of PCL COVID19 Ag Rapid FIA diagnosis, according to the number of days after onset in 62 RT-PCR positive diagnostic samples.



1
2 **Figure 4. Antibody levels against SARS-CoV-2 according to the clinical characteristics of**
3 **the study population.** Levels of antibodies against SARS-CoV-2 between patients with or
4 without underlying illness at different times after symptom onset. The X shape is less than S/CO
5 1, the point is S/CO 1 or more. The red dotted line is S/CO 1(equal to cutoff). 16 patients with
6 seroconversion(PCL COVID19 Total Ab EIA result) were picked up and studied.